The study, published Sept. 20 in Proceedings of the National Academy of Sciences of the U.S., used genetically modified mice with regulated HMGB1 expression and exposed them to asbestos. During the early phases of mesothelioma, the protein was released by mesothelial cells, which began an inflammatory response that overtime prompted the rare cancer to form.
The researchers said they hope their findings can lead to advanced treatments that can help slow the development of mesothelioma.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
